Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ALPL | P05186 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7601178 | 0.87 | HPGDS (0.47) | HTTTSHRMGAMALDH1A1MAP4K4 | |
| SCHEMBL15447361 | 0.87 | MAP4K4 (0.46) | HTTTSHRMGAMMALT1ALDH1A1 | |
| SCHEMBL9508 | 0.85 | MGAM (0.62) | HTTMGAMMALT1ALDH1A1ALPL | |
| SCHEMBL15775057 | 0.83 | ALPL (0.50) | MGAMMALT1ALPLHPGDS | |
| SCHEMBL16127621 | 0.83 | MGAM (0.44) | HTTTSHRMGAMMALT1ALDH1A1 | |
| SCHEMBL1351061 | 0.83 | HTT (0.52) | HTTTSHRMALT1ALDH1A1ALPL | |
| SCHEMBL26623559 | 0.82 | ALPL (0.41) | HTTTSHRMGAMMALT1ALDH1A1 | |
| SCHEMBL31347988 | 0.82 | HDAC6 (0.45) | MGAMMALT1ALPLKDR | |
| SCHEMBL30315874 | 0.80 | MGAM (0.44) | MGAMALDH1A1MAP4K4CSNK1G2CLK4 | |
| SCHEMBL2205670 | 0.79 | ALDH1A1 (0.52) | HTTALDH1A1NPC1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519384-B1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORP (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4519384-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | Promega Corporation (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4519385-A2 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240191211-A1 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION | 2024-06-13 | — | — | US | disclosed |
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION | 2023-11-09 | — | — | US | disclosed |
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION | 2023-11-09 | — | — | US | disclosed |
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION | 2023-11-09 | — | — | US | disclosed |
| WO-2023215497-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215514-A2 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION (US) | 2023-11-09 | — | — | WO | disclosed |
| US-9873716-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9090653-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090653-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140030221-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2014-01-30 | — | — | US | disclosed |
| US-20140030221-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2014-01-30 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2504315-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030221-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | HTT 4373/4885TSHR 3768/4885MGAM 1642/4885 |
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | BTD, HLCS, TYR | HTT 1545/4885TSHR 1644/4885MGAM 4347/4885 |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | HTT 2393/4885TSHR 3276/4885MGAM 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.